Amarin Corporation PLC
NASDAQ:AMRN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Amarin Corporation PLC
Total Liabilities & Equity
Amarin Corporation PLC
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Amarin Corporation PLC
NASDAQ:AMRN
|
Total Liabilities & Equity
$670.8m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
14%
|
|
|
Alkermes Plc
NASDAQ:ALKS
|
Total Liabilities & Equity
$2.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Prothena Corporation PLC
NASDAQ:PRTA
|
Total Liabilities & Equity
$326.8m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-2%
|
|
|
M
|
Mural Oncology PLC
NASDAQ:MURA
|
Total Liabilities & Equity
$169.4m
|
CAGR 3-Years
69%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Amarin Corporation PLC
Glance View
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics for cardiovascular disease management. The firm operates through the development and commercialization of Vascepa segment. Its lead product, Vascepa (icosapent ethyl) capsule for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
See Also
What is Amarin Corporation PLC's Total Liabilities & Equity?
Total Liabilities & Equity
670.8m
USD
Based on the financial report for Dec 31, 2025, Amarin Corporation PLC's Total Liabilities & Equity amounts to 670.8m USD.
What is Amarin Corporation PLC's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
14%
Over the last year, the Total Liabilities & Equity growth was -2%. The average annual Total Liabilities & Equity growth rates for Amarin Corporation PLC have been -9% over the past three years , -7% over the past five years , and 14% over the past ten years .
